Biologics and global burden of asthma: A worldwide portrait and a call for action

Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, rela...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The World Allergy Organization journal Ročník 14; číslo 2; s. 100502
Hlavní autoři: Caminati, M., Morais-Almeida, M., Bleecker, E., Ansotegui, I., Canonica, G.W., Bovo, C., Senna, G.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.02.2021
Elsevier BV
World Allergy Organization
Elsevier
Témata:
Allergies
Asthma
Asthma costs
Asthma mortality
Biological products
Biologics
Chronic obstructive pulmonary disease
Drugs
Health care access
Health care expenditures
High income
Low income groups
Monoclonal antibodies
Morbidity
Mortality
Pharmaceutical industry
Risk factors
Severe asthma
Severe asthma prevalence
Socioeconomic factors
Steroids
South Korea
United States > US
Asia
Japan
Europe
Africa
Israel
North America
Russia
Asthma costs
Severe asthma
Severe asthma prevalence
Asthma mortality
Biologics
ISSN:1939-4551, 1939-4551
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, related with the trend of asthma mortality rate, as a marker of the burden of the disease. A decline in the global rate of annual asthma mortality was observed until the 1980s, but overall no further reduction occurred, and the current mortality estimation is 0.19 deaths per 100.000 people. A higher mortality rate has been registered in low and middle-income countries (LMICs), where poor socioeconomic conditions and lack of access to the medical resources are more relevant. The availability of monoclonal antibodies is mainly limited to the developed and high-income countries. Furthermore the overall “asthma management system” in LMICs suffers from a number of restrictions that hamper the widespread availability of biologics besides their costs. The availability of generic drugs in the field of biologics for severe asthma could contribute to facilitate their widespread accessibility. But before that, awareness and expertise regarding severe asthma, and proper tools to assess and manage it, deserve to be shared worldwide. Collaboration projects involving physicians from all the countries through the scientific Academies network and with the support of the Companies active in the field may provide an initial concrete opportunity.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1939-4551
1939-4551
DOI:10.1016/j.waojou.2020.100502